<unk>  has been used to successfully treat both inflammatory disorders and cancers in the past ten years. There are multiple mechanisms of action, and they can be simplified by organizing them as mechanisms of action in vitro and in vivo. In vitro,<unk>  has three main activities: direct anti-tumor effect, inhibition of angiogenesis, and immunomodulation. In vivo,<unk>  induces tumor cell apoptosis directly and indirectly by inhibition of bone marrow stromal cell support, by anti-angiogenic and anti-osteoclastogenic effects, and by immunomodulatory activity.<unk>  has a broad range of activities that can be exploited to treat many hematologic and solid cancers. On a molecular level,<unk>  has been shown to interact with the ubiquitin E3 ligase cereblon and target this enzyme to degrade the Ikaros transcription factors IKZF1 and IKZF3. This mechanism was unexpected as it suggests that the major action of<unk>  is to re-target the activity of an enzyme rather than block the activity of an enzyme or signaling process, and thereby represents a novel mode of drug action. A more specific implication of this mechanism is that the teratogenic and anti-neoplastic properties of<unk> , and perhaps other thalidomide derivatives, could be disassociated.
Lenalidomide
Ruxolitinib
Pomalidomide
Vincristine
Bortezomib
Rituximab
Ibrutinib
Alemtuzumab